Neil J. Hayward
Oprichter bij eXIthera Pharmaceuticals, Inc.
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Russell Herndon | M | 65 |
Hydra Biosciences, Inc.
 Hydra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA. | 18 jaar |
| William H. Koster | M | 79 |
eXIthera Pharmaceuticals, Inc.
 eXIthera Pharmaceuticals, Inc. BiotechnologyHealth Technology eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA. | - |
| Frans Stassen | M | - |
eXIthera Pharmaceuticals, Inc.
eXIthera Pharmaceuticals, Inc. BiotechnologyHealth Technology eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA. | - |
| Robert Ruffolo | M | 74 |
eXIthera Pharmaceuticals, Inc.
eXIthera Pharmaceuticals, Inc. BiotechnologyHealth Technology eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA. | - |
| Paul Wotton | M | 63 |
eXIthera Pharmaceuticals, Inc.
eXIthera Pharmaceuticals, Inc. BiotechnologyHealth Technology eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA. | - |
| Scott Yaphe | M | - |
eXIthera Pharmaceuticals, Inc.
eXIthera Pharmaceuticals, Inc. BiotechnologyHealth Technology eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA. | 10 jaar |
| Fred Meyer | M | - |
eXIthera Pharmaceuticals, Inc.
eXIthera Pharmaceuticals, Inc. BiotechnologyHealth Technology eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA. | - |
| Assaf Segal | M | 51 |
eXIthera Pharmaceuticals, Inc.
eXIthera Pharmaceuticals, Inc. BiotechnologyHealth Technology eXIthera Pharmaceuticals, Inc. develops and manufactures stroke prevention and antithrombosis drugs. Its drugs are based on the pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. The firm’s drug candidates are small, orally active, and highly selective Factor XI inhibitors. The company was founded by Neil J. Hayward and Frans L. Stassen in 2012 and is headquartered in Westborough, MA. | 5 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Thomas Joseph Burke | M | - |
Hydra Biosciences, Inc.
Hydra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA. | 11 jaar |
| Glenn Larsen | M | 70 |
Hydra Biosciences, Inc.
Hydra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA. | 7 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 10 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Neil J. Hayward
- Persoonlijk netwerk
